JP7472019B2 - 狂犬病ウイルスワクチン - Google Patents

狂犬病ウイルスワクチン Download PDF

Info

Publication number
JP7472019B2
JP7472019B2 JP2020524280A JP2020524280A JP7472019B2 JP 7472019 B2 JP7472019 B2 JP 7472019B2 JP 2020524280 A JP2020524280 A JP 2020524280A JP 2020524280 A JP2020524280 A JP 2020524280A JP 7472019 B2 JP7472019 B2 JP 7472019B2
Authority
JP
Japan
Prior art keywords
vaccine
rabies
rabies virus
rna replicon
alphavirus rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501757A (ja
Inventor
ターピー，イアン
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2021501757A publication Critical patent/JP2021501757A/ja
Priority to JP2023165953A priority Critical patent/JP7714009B2/ja
Application granted granted Critical
Publication of JP7472019B2 publication Critical patent/JP7472019B2/ja
Priority to JP2025119014A priority patent/JP2025169249A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020524280A 2017-11-06 2018-11-05 狂犬病ウイルスワクチン Active JP7472019B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023165953A JP7714009B2 (ja) 2017-11-06 2023-09-27 狂犬病ウイルスワクチン
JP2025119014A JP2025169249A (ja) 2017-11-06 2025-07-15 狂犬病ウイルスワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581955P 2017-11-06 2017-11-06
US62/581,955 2017-11-06
PCT/EP2018/080086 WO2019086645A1 (en) 2017-11-06 2018-11-05 Rabies virus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023165953A Division JP7714009B2 (ja) 2017-11-06 2023-09-27 狂犬病ウイルスワクチン

Publications (2)

Publication Number Publication Date
JP2021501757A JP2021501757A (ja) 2021-01-21
JP7472019B2 true JP7472019B2 (ja) 2024-04-22

Family

ID=64316485

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524280A Active JP7472019B2 (ja) 2017-11-06 2018-11-05 狂犬病ウイルスワクチン
JP2023165953A Active JP7714009B2 (ja) 2017-11-06 2023-09-27 狂犬病ウイルスワクチン
JP2025119014A Pending JP2025169249A (ja) 2017-11-06 2025-07-15 狂犬病ウイルスワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023165953A Active JP7714009B2 (ja) 2017-11-06 2023-09-27 狂犬病ウイルスワクチン
JP2025119014A Pending JP2025169249A (ja) 2017-11-06 2025-07-15 狂犬病ウイルスワクチン

Country Status (8)

Country Link
US (1) US11992526B2 (enExample)
EP (1) EP3706791A1 (enExample)
JP (3) JP7472019B2 (enExample)
CN (2) CN118490817A (enExample)
AU (2) AU2018360288B2 (enExample)
BR (1) BR112020008240A2 (enExample)
CA (1) CA3080425A1 (enExample)
WO (1) WO2019086645A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
EP4149532A1 (en) 2020-05-11 2023-03-22 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
CA3198118A1 (en) 2020-11-12 2022-05-19 Martijn Alexander LANGEREIS Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof
US11730804B1 (en) * 2022-04-13 2023-08-22 Replicate Bioscience, Inc. Compositions and methods for the prevention and treatment of rabies virus infection
CN121045344A (zh) * 2023-12-15 2025-12-02 烟台派诺生物技术有限公司 狂犬病病毒g蛋白突变体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537761A (ja) 2004-05-18 2007-12-27 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
JP2014500013A (ja) 2010-11-05 2014-01-09 ノババックス，インコーポレイテッド 狂犬病糖タンパク質ウイルス様粒子（ｖｌｐ）

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208161B1 (en) * 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
MX2014004214A (es) * 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537761A (ja) 2004-05-18 2007-12-27 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
JP2014500013A (ja) 2010-11-05 2014-01-09 ノババックス，インコーポレイテッド 狂犬病糖タンパク質ウイルス様粒子（ｖｌｐ）
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUNDSTROM, K.，Vaccines，2016年，Vol. 4、No.4, Article No. 39，pp. 1-23
SAXENA, S. et al.，Vet Microbiol，2009年，Vol. 136、No. 1-2，pp. 36-44
THOMPSON, J.M. et al.，Proc Nat Aca Sci U S A，2006年，Vol. 103、No. 10，pp. 3722-3727

Also Published As

Publication number Publication date
AU2018360288B2 (en) 2025-05-22
AU2018360288A1 (en) 2020-05-07
US20200345832A1 (en) 2020-11-05
JP7714009B2 (ja) 2025-07-28
JP2024001076A (ja) 2024-01-09
RU2020117697A (ru) 2021-12-08
BR112020008240A2 (pt) 2020-11-17
CA3080425A1 (en) 2019-05-09
AU2025220796A1 (en) 2025-09-11
JP2021501757A (ja) 2021-01-21
RU2020117697A3 (enExample) 2022-03-03
JP2025169249A (ja) 2025-11-12
WO2019086645A1 (en) 2019-05-09
US11992526B2 (en) 2024-05-28
CN111315409A (zh) 2020-06-19
CN118490817A (zh) 2024-08-16
EP3706791A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
JP7714009B2 (ja) 狂犬病ウイルスワクチン
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
JP7721604B2 (ja) ネコカリシウイルスワクチン
JP7742695B2 (ja) 多価ネコワクチン
US20240398934A1 (en) Feline leukemia virus vaccine
US11167027B2 (en) Multivalent feline vaccine
RU2782350C2 (ru) Вакцина против вируса бешенства
US20240269259A1 (en) Rabies virus vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240410

R150 Certificate of patent or registration of utility model

Ref document number: 7472019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150